慢性肾脏病中心房颤动的流行病学、机制与卒中防治
本文为叙述性综述,总结成人CKD患者心房颤动的流行病学、危险因素、机制和治疗。CKD患者AF患病率显著高于一般人群,可达25%,透析患者达30%,与卒中、心衰及肾衰竭进展风险增加相关。CKD患者AF治疗常不充分,缺乏高级别RCT证据。
要点
- CKD患者AF患病率随肾功能下降而升高,透析患者可达30%。
- AF与CKD双向关联,涉及传统及CKD特有危险因素和多种病理机制。
- CKD患者AF治疗不足,尤其晚期CKD缺乏稳健RCT证据。
核心结论
- CKD患者AF患病率和发病率显著高于一般人群,且与卒中、心衰和肾衰竭进展风险增加相关。
- CKD患者AF治疗常不充分,部分因缺乏尤其晚期CKD的稳健随机临床试验数据。
研究设计与样本
- 叙述性综述,总结成人CKD患者AF的流行病学、危险因素、机制和治疗文献。
主要发现
- AF影响高达25%的CKD患者和30%接受慢性透析的患者。
- AF与卒中、心力衰竭、心肌功能障碍和进展至肾衰竭的风险增加相关。
- AF与CKD的双向关系由传统危险因素(如高血压和糖尿病)与CKD特有异常共同驱动。
- 关键病理生理机制包括全身性炎症、氧化应激、自主神经功能障碍和矿物质代谢紊乱。
临床怎么用
- CKD患者AF治疗选择包括抗凝、控制心室率和节律药物、其他心血管治疗(如SGLT2抑制剂)及节律正常化操作。
- 临床需关注CKD患者AF治疗不足问题,尤其晚期CKD证据有限。
局限性
- 缺乏尤其晚期CKD的稳健随机临床试验数据,影响治疗决策证据强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) is the most common sustained arrhythmia, with a prevalence and incidence significantly higher in adults with CKD compared with the general population. This risk increases with reduced kidney function, affecting up to 25% of all patients with CKD and 30% of those on receiving chronic dialysis. AF is associated with increased morbidity and mortality, including higher risks of stroke, heart failure, myocardial dysfunction, and progression to kidney failure. The bidirectional relationship between AF and CKD is driven by a convergence of traditional risk factors-such as hypertension and diabetes-and CKD-specific abnormalities. Key pathophysiologic mechanisms include systemic inflammation, oxidative stress, autonomic dysfunction, and disordered mineral metabolism. These factors promote structural remodeling, atrial fibrosis, and electrical instability, creating a highly arrhythmogenic substrate. Treatment options for AF include anticoagulation, rate and rhythm control medications, other cardiovascular therapies ( e.g ., sodium glucose cotransporter 2 inhibitors), and procedures aimed at normalizing rhythm and reducing stroke risk. Patients with CKD are often undertreated with AF medications and procedures, in part because of lack of robust randomized clinical trial data on efficacy and safety, particularly with advanced CKD. This narrative review summarizes key literature on the epidemiology, risk factors, mechanisms and treatment of AF in adults with CKD, and highlights critical areas for future research.
引用
- Bansal N, Charytan DM, Garg AX, et al. Atrial Fibrillation and Stroke Prevention and Management in CKD. Clin J Am Soc Nephrol. 2026. PMID: 42335043. doi:10.2215/CJN.0000001159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。